Subtypes of inflammatory eye diseases associated with etanercept. Results are expressed as mean ± SD.
| Inflammatory Eye Disease | N | Age, yrs, sex | Rheumatic Disease | Disease Duration, yrs | Extraarticular Manifestations | Duration of Etanercept Treatment, mo | Dechallenge/rechallenge |
|---|---|---|---|---|---|---|---|
| Scleritis | 11 | 56.1 ± 9.7 | RA | 15.4 ± 9.4 | 2 cutaneous nodules | 12.8 ± 9.3 | 7 dechallenge |
| 10F/1M | 1 dechallenge-rechallenge | ||||||
| Uveitis | 33 | 39.2 ± 12.9 | 14 AS | 11.3 ± 8.3 | 3 prior uveitis | 14.1 ± 9.8 | 18 dechallenge |
| 17F/6M | 10 JIA | 1 cutaneous nodules | 6 dechallenge-rechallenge | ||||
| 2 PSA | 4 not available | ||||||
| 7 RA | |||||||
| Orbital myositis | 1 | 42/F | RA | 5 | 0 | 5 | Not available |
RA: rheumatoid arthritis; AS: ankylosing spondylitis; JIA: juvenile idiopathic arthritis; PSA: psoriatic arthritis.